SCHEMBL264201

SCHEMBL264201

O=C(O)c1cnon1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL19119332 0.98
SCHEMBL3949132 0.78
SCHEMBL11188780 0.73
SCHEMBL27337137 0.70 CYP1A2 (0.35)
Acetic Acid SCHEMBL28903973 0.65 GABRP (0.33)
SCHEMBL69399 0.65 KDM4E (0.55)
Acetic Acid SCHEMBL30664054 0.64
SCHEMBL70035 0.64 KDM4E (0.59)
SCHEMBL277059 0.61
SCHEMBL7767700 0.61 KDM4E (0.56)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110167944-B Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors 联合疗法公司 2024-08-23 CN claimed
EP-3551632-B1 SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS UNION THERAPEUTICS AS (DK) 2024-06-12 EP claimed
EP-3523297-B1 NOVEL FURAZAN-3-CARBOXYLIC ACID DERIVATIVES AND USE THEREOF IN TREATMENT OF CANCER UNIV BERLIN FREIE (DE) 2021-07-07 EP claimed
US-10683286-B2 Furazan-3-carboxylic acid derivatives and use thereof in treatment of cancer FREIE UNIVERSITAET BERLIN (DE) 2020-06-16 US claimed
EP-3523297-A1 NOVEL FURAZAN-3-CARBOXYLIC ACID DERIVATIVES AND USE THEREOF IN TREATMENT OF CANCER Freie Universität Berlin (DE) 2019-08-14 EP claimed
WO-2018065536-A1 NOVEL FURAZAN-3-CARBOXYLIC ACID DERIVATIVES AND USE THEREOF IN TREATMENT OF CANCER FREIE UNIVERSITÄT BERLIN (DE) 2018-04-12 WO claimed
EP-3305783-A1 NOVEL FURAZAN-3-CARBOXYLIC ACID DERIVATIVES AND USE THEREOF IN TREATMENT OF CANCER Freie Universität Berlin (DE) 2018-04-11 EP claimed
EP-1899296-B1 HISTAMINE-3 RECEPTOR ANTAGONISTS PFIZER PROD INC (US) 2010-11-17 EP claimed
US-7812040-B2 such as 3-(3-Acetyl-phenyl)-1-[3-(3-chloro-4-pyrrolidin-1-ylmethyl-phenoxy)-cyclobutylmethyl]-1-methyl-urea, used for the treatment of , schizophrenia, Alzheimer's disease, attention-deficit hyperactivity disorder, hypotension, allergies, cardiovascular, gastrointestinal and psychological disorders PFIZER INC. (US) 2010-10-12 US claimed
US-20090131433-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS PFIZER INC. (US) 2009-05-21 US claimed
EP-1899296-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS Pfizer Products Incorporated (US) 2008-03-19 EP claimed
WO-2006136924-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS PFIZER PRODUCTS INC. (US) 2006-12-28 WO claimed
CN-1043140-C Chlorins, isobacteriochlorins, bacteriochlorins, and methods of making the compounds described herein from the beta, beta'-unsubstituted tetrapyrrole macrocycle HOECHST AG (DE) 1999-04-28 CN claimed
CN-1119013-A Hydroxymethyl furazan carboxylic acid derivatives and their use in the treatment of cardiovascular disease CASSELLA FARBWERKE MAINKUR AG (DE) 1996-03-20 CN claimed
EP-3710428-B1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2026-03-25 EP disclosed
US-20250109137-A1 IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2025-04-03 US disclosed
EP-4522596-A1 DIHYDROINDENE DERIVATIVES AS MALT1 INHIBITORS C4X Discovery Limited (GB) 2025-03-19 EP disclosed
CN-1043140-C Chlorins, isobacteriochlorins, bacteriochlorins, and methods of making the compounds described herein from the beta, beta'-unsubstituted tetrapyrrole macrocycle HOECHST AG (DE) 1999-04-28 CN disclosed
CN-1119013-A Hydroxymethyl furazan carboxylic acid derivatives and their use in the treatment of cardiovascular disease CASSELLA FARBWERKE MAINKUR AG (DE) 1996-03-20 CN disclosed
WO-1995019355-A1 FURAZAN CARBOXYLIC ACID DERIVATIVES HOECHST AKTIENGESELLSCHAFT (DE) 1995-07-20 WO disclosed